Back to results
US 11,105,806 B2Granted
Lung cancer markers and uses thereof
AssigneeCelera Corporation
InventorsCharles Birse, Steve Ruben, Marcia Lewis, Mehdi Mesri
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCelera Corporation
InventorsCharles Birse, Steve Ruben, Marcia Lewis, Mehdi Mesri
Estimating the term…
Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
A method comprising detecting the levels of tissue factor pathway inhibitor (TFPI) protein, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) protein, and Cyfra 21-1 (Cyfra) protein in a body fluid sample from a human, detecting an elevated lung cancer biomarker panel when the level of at least one of said proteins is elevated, and administering a therapeutic agent to treat lung cancer to said human when said elevated lung cancer biomarker panel is detected.
A method comprising detecting the levels of proteins consisting of tissue factor pathway inhibitor (TFPI) protein, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) protein, and Cyfra 21-1 (Cyfra) protein in a body fluid sample from a human, detecting an elevated lung cancer biomarker panel when the level of at least one of said proteins is elevated, and administering a therapeutic agent to treat lung cancer to said human when said elevated lung cancer biomarker panel is detected.
Dependencies are inferred from the claim text.